Home
Issues
2022
June 2022 Vol 12, No 3
April 2022 Vol 12, No 2
February 2022 Vol 12, No 1
March 2022 Vol 12 Special Feature
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
ASCO 2022 - Wrap Up
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2022
June 2022 Vol 12, No 3
April 2022 Vol 12, No 2
February 2022 Vol 12, No 1
March 2022 Vol 12 Special Feature
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
ASCO 2022 - Wrap Up
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
JHOP - December 2020 Vol 10, No 6
Case Reports
Original Article
HOPA Abstracts
FDA Oncology Update
Case Reports
Desensitization Permits Continued Trastuzumab and Ado-Trastuzumab Emtansine Therapy After Hypersensitivity Reaction
Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD
Read More
Original Article
Outcomes for Patients Receiving Ibrutinib with or without Antifungal Therapy
Kori Daniels, PharmD, BCOP; Arpita Gandhi, PharmD, BCOP; Locke Bryan, MD; Amber Clemmons, PharmD, BCOP
Read More
The Safety Profile of Mini-Dose Methotrexate for Graft-versus-Host Disease Prophylaxis: Is There a Place for Folinic Acid Rescue?
Loriel J. Solodokin, PharmD, BCOP; Amir Steinberg, MD, FACP; Erin Moshier, MS
Read More
Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience
Vincent J. Cascone, PharmD, BCOP; Kane M. Hosmer, PharmD, BCOP; Zahra Mahmoudjafari, PharmD, BCOP; David W. Henry, MS, RPh, BCOP, FASHP; Dennis W. Grauer, MS, PhD
Read More
Vaccination Rates in Patients with Hematologic Cancers After Hematopoietic Stem-Cell Transplant: A Single-Center Retrospective Study
Hiba Ahmad, PharmD, BCOP; Sarah Perreault, PharmD, BCPS, BCOP; Dayna McManus, PharmD, BCPS-AQ ID; Francine Foss, MD; Iris Isufi, MD; Stuart Seropian, MD; Jeffrey Topal, MD
Read More
HOPA Abstracts
HOPA 2020 Abstracts, Part IV
Read More
FDA Oncology Update
FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
Read More
Danyelza First Drug FDA Approved for High-Risk Neuroblastoma in the Bone and Bone Marrow
Read More
Gavreto, a New RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Read More
Onureg FDA Approved for Adults with AML in Remission
Read More
Gavreto Now Approved for Thyroid Cancer with RET Fusions
Read More
Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer
Read More
Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma
Read More
Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma
Read More
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.